80
Participants
Start Date
October 31, 2006
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
BHT-3021
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
BHT-Placebo
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Royal Melbourne Hospital, Parkville
Eastern Clinical Research Unit, Ringwood East
Peninsula Clinical Research Centre, Kippa-Ring
Fremantle Hospital, Fremantle
MedStar Research Institute, Washington D.C.
University of Miami, Miller School of Medicine, Diabetes Research Institute, Miami
Private Practice, Wellington
University of Alabama at Birmingham School of Medicine, Birmingham
Creighton Diabetes Center, Omaha
Diabetes and Glandular Disease Center, San Antonio
Barbara Davis Center for Childhood Diabetes, Aurora
Private Practice, Denver
Valley Research, Fresno
Benaroya Research Institute at Virginia Mason, Seattle
Middlemore Hospital, Otahuhu
Christchurch Hospital, Christchurch
Waikato Regional Diabetes Service, Hamilton
The Diabetes Centre, Newtown
Lead Sponsor
Bayhill Therapeutics
INDUSTRY